Clinical trial · no report yet · Phase 3
MAGNETISMM-5
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- NCT05020236 ↗
- Recruiting
- Pfizer
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 15 | |
| YouTube | 9 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab; Daratumumab; Pomalidomide; Dexamethasone
- Arms
- Part 1 Safety Lead-In Dose Escalation: Elranatamab + Daratumumab · Experimental
- Part 2 Randomized Arm A: Elranatamab · Experimental
- Part 2 Randomized Arm B: Elranatamab + Daratumumab · Experimental
- Part 2 Randomized Arm C: Daratumumab + Pomalidomide + Dexamethasone · Active comparator
- Part 3 Arm D: Elranatamab · Experimental
- Part 3 Arm E: Elranatamab + Daratumumab · Experimental
- Enrollment
- 893 (estimated)
- Primary outcomes
- Part 1 Safety Lead-In: Incidence of dose limiting toxicities
- Part 2 Randomized: Progression free survival per International Myeloma Working Group criteria
- Part 3: Frequency of treatment-emergent adverse events
- Sponsor
- Pfizer
- Start
- Oct 4, 2021
- Primary completion
- Feb 26, 2026
- Results posted
- No
- Registry record
- NCT05020236 · updated Aug 24, 2026